EML2-AS1

Across TCGA pan-cancer cohorts, EML2-AS1 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated EML2-AS1 data layer.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher EML2-AS1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated EML2-AS1 expression acts as an unfavorable survival marker, although some lineages such as READ and SARC show a favorable association.

ACC, COAD, and BRCA are the cancer types where EML2-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Tertile	All	0.442	0.858	<.001	79	view →
COAD	DFS	Tertile	All	0.374	0.563	.006	63	view →
BRCA	DFS	Median	IV	0.435	0.841	.003	35	view →
MESO	OS	Quartile	All	0.279	0.611	<.001	31	view →
UVM	OS	Quartile	All	0.300	0.717	.001	30	view →
PAAD	DFS	Median	All	0.388	0.608	.001	21	view →
KIRP	DFS	Tertile	III,IV	0.388	0.848	.021	18	view →
KIRC	DFS	Tertile	IV	0.383	0.701	.018	13	view →
THCA	OS	Quartile	IV	0.526	0.910	.002	13	view →
READ	DFS	Quartile	III,IV	1.000	0.296	.010	12	view →
DLBC	DFS	Quartile	II,III,IV	0.343	1.000	.022	8	view →
STAD	DFS	Tertile	IV	0.224	0.607	.010	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

EML2-AS1–ACC (DFS)

Open the ACC breakdown →